Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline

Journals

remove_circle_outline

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = FLT3-ITD allelic load

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 3461 KiB  
Article
Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
by Konstantin Bogdanov, Ekaterina Kudryavtseva, Yulia Fomicheva, Irina Churkina, Elza Lomaia, Larisa Girshova, Yuri Osipov and Andrey Zaritskey
Pathophysiology 2023, 30(3), 296-313; https://doi.org/10.3390/pathophysiology30030024 - 1 Aug 2023
Cited by 1 | Viewed by 1721
Abstract
Mutations in the FLT3 gene not only lead to abnormalities in its structure and function, but also affect the expression of other genes involved in leukemogenesis. This study evaluated the expression of genes that are more characteristic of neuroblastoma but less studied in [...] Read more.
Mutations in the FLT3 gene not only lead to abnormalities in its structure and function, but also affect the expression of other genes involved in leukemogenesis. This study evaluated the expression of genes that are more characteristic of neuroblastoma but less studied in leukemia. N-MYC oncogene expression was found to be more than 3-fold higher in primary AML patients carrying the FLT3-ITD mutation compared to carriers of other mutations as well as patients with normal karyotype (p = 0.03946). In contrast to the expression of several genes (C-MYC, SPT16, AURKA, AURKB) directly correlated to the allelic load of FLT3-ITD, the expression of the N-MYC oncogene is extremely weakly related or independent of it (p = 0.0405). Monitoring of N-MYC expression in some patients with high FLT3-ITD allelic load receiving therapy showed that a decrease in FLT3-ITD allelic load is not always accompanied by a decrease in N-MYC expression. On the contrary, N-MYC expression may remain elevated during the first three months after therapy, which is additional evidence of the emergence of resistance to therapy and progression of AML. Full article
(This article belongs to the Special Issue MYC in Regeneration and Tumorigenesis)
Show Figures

Figure 1

Back to TopTop